Abstract
The article "Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy," was originally published electronically on the publisher's internet portal without open access.
Highlights
decision to opt for Open Choice the copyright of the article changed on
the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License
Bundschuh was originally published electronically on the publisher’s internet portal (currently SpringerLink) on July 16, 2018 without open access
Summary
Morgan Department of Radiology and Radiological Science, Division of Nuclear Medicine and Molecular Imaging, Johns Hopkins University School of Medicine, Baltimore, MD, USA 2Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany 3Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany 4Ambulatory Healthcare Center Dr Neumaier & Colleagues, Radiology, Nuclear Medicine, Radiation Therapy, Regensburg, Germany 5Department of Nuclear Medicine, Medical University of Vienna, Vienna, Austria 6Mediso Medical Imaging Systems Ltd., Budapest, Hungary 7Department of Nuclear Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany 8Department of Bio Medical Imaging, National Cardiovascular and Cerebral Research Center, Suita, Japan 9Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany 10Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
